Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.

about

Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.

Item

http://www.wikidata.org/entity/Q38784143

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Population Pharmacokinetic and ...... oidism Receiving Hemodialysis.

@en

type

Item

label

Population Pharmacokinetic and ...... oidism Receiving Hemodialysis.

@en

prefLabel

Population Pharmacokinetic and ...... oidism Receiving Hemodialysis.

@en

P1476

Population Pharmacokinetic and ...... oidism Receiving Hemodialysis.

@en

P2093

Adimoolam Narayanan

http://www.w3.org/2001/XMLSchema#string

Andrew T Chow

http://www.w3.org/2001/XMLSchema#string

Benjamin Wu

http://www.w3.org/2001/XMLSchema#string

John P Gibbs

http://www.w3.org/2001/XMLSchema#string

Murad Melhem

http://www.w3.org/2001/XMLSchema#string

Per Olsson Gisleskog

http://www.w3.org/2001/XMLSchema#string

Ping Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management.

Biochemistry, physiology and pathophysiology of the extracellular calcium-sensing receptor.

Management of secondary hyperparathyroidism: the gap between diagnosis and treatment. The Renal Osteodystrophy Multicenter Enquiry.

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.

Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis.

Effects of excess PTH on nonclassical target organs.

A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling.

Automated covariate model building within NONMEM.

Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor.

P2888

s40262-017-0550-4

P31

scholarly article

meta-analysis

P356

10.1007/S40262-017-0550-4

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085411696

http://www.w3.org/2001/XMLSchema#string

P698

28508378

http://www.w3.org/2001/XMLSchema#string

P921

hyperparathyroidism